^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zoldonrasib (RMC-9805)

    i
    Company:
    Revolution Medicines
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Apply
    Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors (NCT06040541)
    Phase 1
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    02/01/2024
    Initiation :
    09/07/2023
    Primary completion :
    08/30/2025
    Completion :
    07/31/2026
    KRAS
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    zoldonrasib (RMC-9805)